AI Summary & Key Takeaways
AI InsightResults: Two patients complained of anemia (2.2%) (Hb
📌 3 Key Takeaways
Abstract
Objective: Therapy-related myeloid neoplasms (t-MN) account for approximately 10% to 20% of all cases of AML (acute myeloid leukemia), MDS (myelodysplastic syndrome) and MDS/MPN (myelodysplastic syndrome/myeloproliferative neoplasms), MDS, and MDS/MPN. In our study, we evaluated peripheral blood smear samples and hemogram values in breast cancer patients who were receiving adjuvant anthracycline regimens and were in remission. Materials and Methods: A total of 78 patients receiving anthracycline- based adjuvant chemotherapy treatment from Kayseri Research and Training Hospital and Mersin State Hospital were enrolled in the study. Their adjuvant treatments had been completed at least 18 months prior to the study. Results: Two patients complained of anemia (2.2%) (Hb
Özet
Amaç: Tedaviye bağlı myeloid neoplazmlar, tüm AML,MDS ve MDS/ MPN vakalrının yaklaşık %10-20’sini oluşturmaktadır. Çalışmamızda adjuvant antrasiklinli kemoterapi rejimi almış remisyonda meme kanserli hastaların periferik yayma ve hemogram değerlerini araştırılmıştır. Gereç ve Yöntem: Antrasiklin bazlı kemoterapi rejimi almış ve remisyonda olan toplam 78 hasta Kayseri Eğitim ve Araştırma Hastanesi ile Mersin Devlet Hastanesi’nden çalışmaya alınmıştır. Hastaların remisyonda olması ve tedaviyi en az 18 ay once tamamlamış olmasına dikkat edildi. Bulgular: İki hastada anemi (%2.2) (Hb